Drug Watch

JAK Inhibitors: Drilling Down the Details
November 25, 2021

In this exclusive video interview, James Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the hype around the treatments.

Hyperhidrosis and Emerging Treatments
November 02, 2021

We sit down in a video interview with David Pariser, MD, FACP, FAAD, the secretary and founding member of the International Hyperhidrosis Society to discuss hyperhidrosis identifiers and treatments in honor of Hyperhidrosis Awareness Month.

First Topical JAK Inhibitor Treats Whole-body AD
October 24, 2021

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

New Drugs Tackle Tough Challenges
September 30, 2021

Potential game-changers in the pipeline and newly FDA-approved treatments were highlighted in an overview of new drugs to watch at Maui Derm NP+PA Fall 2021 meeting.

Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators
September 28, 2021

Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.

Pipeline of Promise for Atopic Dermatitis
September 24, 2021

New therapies raise patient expectations for fast efficacy, lower costs, and fewer adverse effects.

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23, 2021

This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.

Pipeline Updates in Melanoma
September 22, 2021

Possible melanoma treatments have had multiple newsworthy events since July 2021.

FDA Approves Ruxolitinib for Atopic Dermatitis
September 21, 2021

Incyte announced the FDA has approved its topical selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib (Opzelura) for the treatment of mild to moderate atopic dermatitis.

Dermatology Times Chief Medical Editor Weighs in On Black Box Warning for JAK Inhibitors
September 21, 2021

In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.